Details for Patent: 10,933,046
Which drugs does patent 10,933,046 protect, and when does it expire?
Patent 10,933,046 protects EPSOLAY and is included in one NDA.
This patent has twelve patent family members in two countries.
Summary for Patent: 10,933,046
| Title: | Method for treatment of rosacea in patients aged 65 years and older | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Ofer Toledano, Ofra Levy-Hacham, Ori NOV, Vered RAM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Mayne Pharma LLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/794,839 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 10,933,046: Benzoyl Peroxide Rosacea Regimen, Claim Scope and Patent LandscapeUS Patent 10,933,046 protects a narrow clinical-use regimen for treating rosacea with once-daily, encapsulated or microencapsulated benzoyl peroxide in patients aged 65 years and older. The claims are directed primarily to treatment outcomes, not merely to the composition. The strongest commercial relevance is to 5% benzoyl peroxide products such as Epsolay, while ordinary benzoyl peroxide acne products generally fall outside the claims unless they satisfy every patient, formulation, dosing, and efficacy limitation. The patent is commercially significant because it combines four limitations that are difficult to establish from product labeling alone: an elderly patient population, rosacea treatment, a single active ingredient, and specified clinical outcomes against vehicle control. What does US Patent 10,933,046 protect?The patent protects methods and compositions involving:
The patent therefore does not broadly cover every topical benzoyl peroxide formulation or every rosacea treatment. It covers a defined therapeutic protocol tied to a defined patient subgroup and specified results. How are the claims organized?Claims 1 through 12: IGA success-rate regimenIndependent claim 1 requires treatment for at least two weeks and an IGA success rate of at least 15% in the treated group. The claim also requires encapsulation or microencapsulation and limits the formulation to benzoyl peroxide as the only active ingredient. The dependent claims create a time-and-response ladder:
Claims 9 through 12 add a 5% concentration, first-line treatment, cream or emulsion dosage forms, and extended-release formulations. Claims 13 and 14: severe rosacea composition-for-use claimsClaims 13 and 14 use a pharmaceutical-composition-for-use format and address severe rosacea in patients aged 65 years and older. Claim 13 incorporates the four treatment durations and corresponding IGA thresholds:
Claim 14 narrows the composition to approximately 5% benzoyl peroxide. Claims 15 through 25: inflammatory-lesion reductionClaims 15 through 25 protect a second efficacy pathway based on the mean percentage decrease in inflammatory lesions from baseline.
Claim 24 adds a second set of values, including approximately 45%, 60%, 69% and 70% reductions for the four treatment periods, compared with vehicle reductions of approximately 29%, 42%, 41% and 41%. The lesion-reduction claims may be important in enforcement because they do not depend exclusively on IGA status. A product can potentially satisfy the claims through documented inflammatory-lesion outcomes even if the sponsor does not characterize its commercial endpoint in the same terms. What is the core infringement test under US Patent 10,933,046?A potentially infringing product or regimen must satisfy every limitation of an asserted claim. For the principal independent claims, the relevant questions are:
A generic or follow-on sponsor would not ordinarily be exposed merely because it markets a 5% benzoyl peroxide cream. The exposure increases if the product is positioned for rosacea, uses an encapsulated delivery system, and relies on the same once-daily clinical protocol. The “sole active ingredient administered” limitation is narrower than a conventional “only active ingredient in the composition” limitation. It can implicate concomitant therapies used during a clinical trial or commercial treatment course. A sponsor that instructs patients to use metronidazole, ivermectin, azelaic acid or another active rosacea therapy may argue that the regimen does not meet the claimed monotherapy requirement. That argument depends on the prescribing instructions, clinical protocol, product labeling and actual use evidence. How strong are the patent claims?StrengthsThe claims have several features that can create meaningful enforcement leverage:
The formulation and age limitations also make a simple anticipation reference less likely. A prior-art document may disclose benzoyl peroxide for rosacea, but it must disclose the claimed concentration, delivery system, elderly population, dosing schedule and outcome limitations in the required combination. VulnerabilitiesThe claims also present litigation and validity risks. First, benzoyl peroxide was widely known for dermatological use before the patent family’s filing. Prior art concerning benzoyl peroxide for acne, rosacea, follicular disease or inflammatory skin conditions could support an obviousness challenge when combined with known topical delivery technologies. Second, the result limitations may invite written-description and enablement challenges. The patent must adequately support the claimed clinical outcomes across the full concentration range of approximately 2.5% to 10%, the full elderly population, the specified rosacea subtypes, and the claimed treatment durations. Third, the claims use “about” for concentrations and clinical percentages. That language provides flexibility but creates construction disputes over the permitted numerical range. Fourth, the claims refer to an “investor global assessment” scale. In dermatology, the standard term is generally “Investigator’s Global Assessment.” The apparent terminology issue may create an interpretation dispute, although courts commonly construe an obvious drafting error in light of the specification and prosecution history. Fifth, claims 13 and 23 refer to severe rosacea, while the principal regimen claims do not expressly require severe disease. This difference affects both validity and infringement analysis. The broader claims may face more prior-art exposure; the severe-rosacea claims may be narrower but easier to map to a labeled indication if the product is approved for moderate-to-severe disease. What formulation technology is protected?The claims require that benzoyl peroxide be “encapsulated or microencapsulated.” This is a material limitation. A conventional non-encapsulated benzoyl peroxide cream would generally not satisfy the literal formulation requirement. The patent does not, based on the supplied claims, require a particular:
Claims 11 and 21 expressly identify creams and emulsions. Claims 12 and 22 identify extended-release formulations. The independent claims, however, do not appear limited to a cream, emulsion or specific release mechanism. A non-cream encapsulated formulation could therefore remain within the independent claim scope if all other limitations are satisfied. The formulation limitation is likely linked to the commercial differentiation of Epsolay. Epsolay is a 5% benzoyl peroxide cream approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. Its delivery technology is designed to improve tolerability relative to conventional benzoyl peroxide products. The product label identifies benzoyl peroxide as the active ingredient and instructs once-daily application.[1] What is the FDA and Orange Book status?The FDA approved Epsolay, a 5% benzoyl peroxide cream, for the treatment of inflammatory lesions of rosacea in adults in April 2022. The product is associated with Galderma Laboratories, L.P., while the underlying formulation and patent estate originated with Sol-Gel Technologies Ltd. or related entities.[1][2] The relevant regulatory distinction is important:
A patent directed to a method of use may be listed in the Orange Book when it claims an approved method of using the drug product. Composition and formulation patents may also be listed when they claim the approved product. Orange Book status should therefore be assessed by patent number, expiration date, use code and the specific NDA listing rather than by the presence of the patent in a broader patent family.[3] The supplied claim set does not establish the current Orange Book listing status, use code or any terminal-disclaimer adjustment for US 10,933,046. Those items are regulatory-record facts rather than matters that can be determined from the claims alone. When does US Patent 10,933,046 lose exclusivity?The patent was granted in 2022. Its enforceable term is governed by the earliest effective nonprovisional filing date in the family, subject to patent-term adjustment, patent-term extension and any terminal disclaimer. A reliable expiration date cannot be calculated from the claims provided. For commercial planning, the patent should be treated as a later-expiring use or formulation asset in the Epsolay estate rather than as the sole exclusivity right. FDA exclusivity and other related patents may create separate barriers. The controlling dates are:
A generic applicant must evaluate the full patent family and FDA listing, not just US 10,933,046. Which companies could challenge the patent?Potential challengers include:
A Paragraph IV challenge would likely focus on anticipation, obviousness, written description, enablement, indefiniteness and non-infringement. The strongest non-infringement position would involve a formulation that is not encapsulated or microencapsulated, a concentration outside the claimed range, or a label that does not direct treatment of rosacea in patients aged 65 years and older. The strongest invalidity theories would likely combine:
A generic label that omits the patented elderly population may reduce induced-infringement risk, but it does not eliminate all exposure. Actual prescribing, promotional materials and physician instructions can become relevant in a litigation record. What litigation and settlement risks exist?A Paragraph IV filing against an Orange Book-listed product could trigger patent litigation under the Hatch-Waxman Act and a potential 30-month stay of FDA approval, subject to statutory exceptions and listing-specific facts.[4] The settlement outcome would depend on the patent family, the challenged claims and the proposed generic label. Potential settlement structures include:
The claims’ elderly-population limitation may support a negotiated carve-out if the generic sponsor can market benzoyl peroxide for acne or other dermatological indications without directing use for rosacea in patients aged 65 and older. No litigation or settlement can be attributed to US 10,933,046 from the claim text alone. Patent litigation status must be confirmed through PACER, district-court dockets, the Federal Circuit docket and FDA Paragraph IV records. How does Epsolay compare with conventional benzoyl peroxide products?
The patent estate is strongest against a directly substitutable 5% encapsulated product marketed for rosacea. It is weaker against an unencapsulated acne product or a product whose label excludes rosacea treatment. What generic launch scenarios are most plausible?Scenario 1: Same 5% encapsulated formulationThis presents the highest risk. A generic would need to address the formulation claims, method claims and any related patents. A Paragraph IV litigation strategy would be likely if the commercial opportunity is large enough. Scenario 2: Non-encapsulated 5% formulationThis may avoid literal infringement of the claims requiring encapsulation or microencapsulation. The sponsor would still need to address any separate patents covering benzoyl peroxide concentration, rosacea treatment or formulation components. Scenario 3: Rosacea label excluding patients aged 65 years and olderThis could reduce literal infringement risk under the supplied claims. It may not be commercially attractive if the product’s principal target population includes older adults. Scenario 4: Alternative active ingredientMetronidazole, ivermectin and azelaic acid products would generally fall outside these benzoyl peroxide claims. They may face separate patent, regulatory or exclusivity barriers. Key Takeaways
FAQsDoes US 10,933,046 cover all 5% benzoyl peroxide creams?No. The supplied claims require encapsulated or microencapsulated benzoyl peroxide and additional rosacea, age, dosing and efficacy limitations. Can a generic avoid the patent by labeling the product only for acne?Potentially. An acne-only label may avoid the claimed rosacea regimen, but the sponsor must evaluate induced-infringement risk, actual marketing conduct and other patents in the family. Does the patent cover treatment of patients younger than 65?The supplied claims require subjects aged 65 years and older. Treatment of younger patients does not literally satisfy that age limitation. Are the IGA thresholds product characteristics?They are claim limitations tied to treatment outcomes in a group of patients. They are not simply physical characteristics of the cream and may require clinical or real-world evidence to establish infringement. Does FDA approval prove infringement of US 10,933,046?No. FDA approval establishes regulatory authorization for the approved product and indication. Patent infringement depends on whether the accused product and use satisfy every limitation of an asserted claim. References
More… ↓ |
Drugs Protected by US Patent 10,933,046
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | EPSOLAY | benzoyl peroxide | CREAM;TOPICAL | 214510-001 | Apr 22, 2022 | RX | Yes | Yes | 10,933,046 | ⤷ Start Trial | Y | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,933,046
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3130362 | ⤷ Start Trial | |||
| Canada | 3130437 | ⤷ Start Trial | |||
| Canada | 3130439 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
